Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Limited is engaged in the marketing of pharmaceutical products in domestic and international markets. The company is also engaged in distribution of pharmaceutical products through third-party distribution network.[1]It is a part of the Trident Texofab Group
- Market Cap ₹ 202 Cr.
- Current Price ₹ 176
- High / Low ₹ 240 / 123
- Stock P/E 28.5
- Book Value ₹ 42.4
- Dividend Yield 0.00 %
- ROCE 25.1 %
- ROE 23.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.55%
- Debtor days have increased from 82.5 to 140 days.
- Working capital days have increased from 129 days to 307 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|
| 4.93 | 9.62 | 21.77 | 31.69 | 36.45 | |
| 5.20 | 8.37 | 19.05 | 25.42 | 28.58 | |
| Operating Profit | -0.27 | 1.25 | 2.72 | 6.27 | 7.87 |
| OPM % | -5.48% | 12.99% | 12.49% | 19.79% | 21.59% |
| 0.07 | 0.16 | 0.60 | 1.15 | 1.74 | |
| Interest | 0.76 | 0.41 | 0.13 | 0.48 | 0.48 |
| Depreciation | 0.12 | 0.14 | 0.20 | 0.36 | 0.54 |
| Profit before tax | -1.08 | 0.86 | 2.99 | 6.58 | 8.59 |
| Tax % | 25.93% | 25.58% | -32.11% | 8.51% | |
| -0.80 | 0.63 | 3.95 | 6.01 | 7.10 | |
| EPS in Rs | -2.58 | 1.26 | 4.94 | 5.23 | 6.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 86% |
| TTM: | 46% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 111% |
| TTM: | 52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 24% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|
| Equity Capital | 3.10 | 5.00 | 8.00 | 11.50 | 11.50 |
| Reserves | -6.10 | -5.47 | -3.22 | 34.13 | 37.24 |
| 6.46 | 4.53 | 2.46 | 3.38 | 2.93 | |
| 2.93 | 7.39 | 6.59 | 7.49 | 8.04 | |
| Total Liabilities | 6.39 | 11.45 | 13.83 | 56.50 | 59.71 |
| 0.77 | 1.18 | 1.43 | 3.11 | 4.32 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.23 | 0.36 |
| Investments | 0.00 | 0.00 | 0.05 | 4.04 | 4.26 |
| 5.62 | 10.27 | 12.35 | 49.12 | 50.77 | |
| Total Assets | 6.39 | 11.45 | 13.83 | 56.50 | 59.71 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| -0.59 | 1.48 | -0.19 | -16.60 | |
| -0.08 | -0.56 | -0.50 | -5.56 | |
| 0.76 | -0.96 | 0.80 | 35.80 | |
| Net Cash Flow | 0.08 | -0.03 | 0.11 | 13.64 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| Debtor Days | 96.99 | 24.28 | 83.33 | 139.94 |
| Inventory Days | 103.66 | 349.10 | 95.16 | 129.36 |
| Days Payable | 201.80 | 266.30 | 134.15 | 86.78 |
| Cash Conversion Cycle | -1.15 | 107.09 | 44.34 | 182.52 |
| Working Capital Days | -11.85 | 11.76 | 66.73 | 307.18 |
| ROCE % | 33.78% | 55.22% | 25.10% |
Documents
Announcements
-
Update on board meeting
21 Apr - The Board Meeting to be held on 22/04/2024 has been revised to 27/04/2024 The Board Meeting to be held on 22/04/2024 has been rescheduled to …
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
15 Apr - The Ministry of Corporate Affairs has approved incorporation of 'TLL ELEMENTS PRIVATE LIMITED' (CIN: U20237GJ2024PTC150636) on 15th April, 2024 and has issued a Certificate of …
-
Compliance Certificate Under Regulation 40(10) Of SEBI (LODR) Regulations, 2015
13 Apr - Listing Obligations and Disclosures Requirements) Regulations, 2015, we are enclosing herewith copy of the Compliance Certificate under Regulation 40(9) of Listing Regulations duly certified by …
- Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results For The Half Year And Year Ended 31St March, 2024. 13 Apr
- Disclosure Of Material Events Under Regulation 30 Of SEBI (LODR) Regulations, 2015 10 Apr
Business categories[1]
1. Ethical marketing of pharmaceutical formulation & products in International Markets through a third-party distribution network and sales force under its own brand
2. Getting approved formulations manufactured through Contract Manufacturers, Source & Supply of Generic Pharma formulation and medicines in Domestic and International Market.
The company is working on Asset-light third-party contract manufacturing model.